Disulfide Based Prodrugs for Cancer Therapy

Overview

Journal RSC Adv

Publisher Royal Society of Chemistry

Specialty Chemistry

Date 2022 May 6

PMID 35516223

Authors

Qiang Wang

Jiankun Guan

Jiangling Wan

Zifu Li

Affiliations

Soon will be listed here.

Abstract

Advances in the tumor microenvironment have facilitated the development of novel anticancer drugs and delivery vehicles for improved therapeutic efficacy and decreased side effects. Disulfide bonds with unique chemical and biophysical properties can be used as cleavable linkers for the delivery of chemotherapeutic drugs. Accordingly, small molecule-, peptide-, polymer- and protein-based multifunctional prodrugs bearing cleavable disulfide bonds are well accepted in clinical settings. Herein, we first briefly introduce a number of prodrugs and divide them into three categories, namely, disulfide-containing small molecule conjugates, disulfide-containing cytotoxic agent-targeted fluorescent agent conjugates, and disulfide-containing cytotoxic agent-macromolecule conjugates. Then, we discuss the complex redox environment and the underlying mechanism of free drug release from disulfide based prodrugs in settings. Based on these insights, we analyze the impact of electronics, steric hindrance and substituent position of the disulfide linker on the extracellular stability and intracellular cleavage rate of disulfide containing prodrugs. Current challenges and future opportunities for the disulfide linker are provided at the end.

Citing Articles

Introducing Regioselective Disulfide Linkages in Peptides under Pseudodilute Conditions by Harnessing Bro̷nsted Acid-Activated -Chlorosuccinimide.

Tripathi N, Das B, Chowdhury A, Gour V, Bandyopadhyay A JACS Au. 2025; 5(2):802-810.

PMID: 40017760 PMC: 11862937. DOI: 10.1021/jacsau.4c01063.

Hydrophilic Ethylene Glycol Fragments: A Determinant Affecting the Therapeutic Index of Paclitaxel Prodrug Nanoassemblies.

Li Y, Sun Y, Wang Q, Wang S, Liu C, Huang Y ACS Cent Sci. 2024; 10(12):2253-2265.

PMID: 39735304 PMC: 11672549. DOI: 10.1021/acscentsci.4c01004.

Stabilized Carbon Radical-Mediated Assembly of Arylthianthrenium Salts, Alkenes and Amino Acid/Peptide Derivatives.

Dong B, Qi W, Chen Y, Zhang Y, Gu S, Zhao J Adv Sci (Weinh). 2024; 12(2):e2411579.

PMID: 39573977 PMC: 11727398. DOI: 10.1002/advs.202411579.

Biodegradable Natural Hydrogels for Tissue Engineering, Controlled Release, and Soil Remediation.

Garcia-Garcia A, Munana-Gonzalez S, Lanceros-Mendez S, Ruiz-Rubio L, Alvarez L, Vilas-Vilela J Polymers (Basel). 2024; 16(18).

PMID: 39339063 PMC: 11435712. DOI: 10.3390/polym16182599.

Design of pH/Redox Co-Triggered Degradable Diselenide-Containing Polyprodrug via a Facile One-Pot Two-Step Approach for Tumor-Specific Chemotherapy.

Hu Y, Liu P Molecules. 2024; 29(16).

PMID: 39202916 PMC: 11357291. DOI: 10.3390/molecules29163837.

References

Zhang D, Fourie-ODonohue A, Dragovich P, Pillow T, Sadowsky J, Kozak K . Catalytic Cleavage of Disulfide Bonds in Small Molecules and Linkers of Antibody-Drug Conjugates. Drug Metab Dispos. 2019; 47(10):1156-1163. DOI: 10.1124/dmd.118.086132. View

Li Y, Yang H, Yao J, Yu H, Chen X, Zhang P . Glutathione-triggered dual release of doxorubicin and camptothecin for highly efficient synergistic anticancer therapy. Colloids Surf B Biointerfaces. 2018; 169:273-279. DOI: 10.1016/j.colsurfb.2018.05.025. View

Lewis Phillips G, Li G, Dugger D, Crocker L, Parsons K, Mai E . Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008; 68(22):9280-90. DOI: 10.1158/0008-5472.CAN-08-1776. View

Santra S, Kaittanis C, Santiesteban O, Perez J . Cell-specific, activatable, and theranostic prodrug for dual-targeted cancer imaging and therapy. J Am Chem Soc. 2011; 133(41):16680-8. PMC: 3198802. DOI: 10.1021/ja207463b. View

Betz S . Disulfide bonds and the stability of globular proteins. Protein Sci. 1993; 2(10):1551-8. PMC: 2142256. DOI: 10.1002/pro.5560021002. View

Brulisauer L, Gauthier M, Leroux J . Disulfide-containing parenteral delivery systems and their redox-biological fate. J Control Release. 2014; 195:147-54. DOI: 10.1016/j.jconrel.2014.06.012. View

Pei Q, Hu X, Wang L, Liu S, Jing X, Xie Z . Cyclodextrin/Paclitaxel Dimer Assembling Vesicles: Reversible Morphology Transition and Cargo Delivery. ACS Appl Mater Interfaces. 2017; 9(32):26740-26748. DOI: 10.1021/acsami.7b08110. View

Zhang D, Pillow T, Ma Y, Dela Cruz-Chuh J, Kozak K, Sadowsky J . Linker Immolation Determines Cell Killing Activity of Disulfide-Linked Pyrrolobenzodiazepine Antibody-Drug Conjugates. ACS Med Chem Lett. 2016; 7(11):988-993. PMC: 5108036. DOI: 10.1021/acsmedchemlett.6b00233. View

Han L, Zhang X, Wang Y, Li X, Yang X, Huang M . Redox-responsive theranostic nanoplatforms based on inorganic nanomaterials. J Control Release. 2017; 259:40-52. DOI: 10.1016/j.jconrel.2017.03.018. View

10.

Jiang Z, Thayumanavan S . Disulfide-containing Macromolecules for Therapeutic Delivery. Isr J Chem. 2021; 60(1-2):132-139. PMC: 8221575. DOI: 10.1002/ijch.201900160. View

11.

He W, Hu X, Jiang W, Liu R, Zhang D, Zhang J . Rational Design of a New Self-Codelivery System from Redox-Sensitive Camptothecin-Cytarabine Conjugate Assembly for Effectively Synergistic Anticancer Therapy. Adv Healthc Mater. 2017; 6(24). DOI: 10.1002/adhm.201700829. View

12.

Jain A, Gund M, Desai D, Borhade N, Senthilkumar S, Dhiman M . Mutual prodrugs containing bio-cleavable and drug releasable disulfide linkers. Bioorg Chem. 2013; 49:40-8. DOI: 10.1016/j.bioorg.2013.06.007. View

13.

Kim T, Jeon H, Le H, Kim T, Kang C, Kim J . A biotin-guided fluorescent-peptide drug delivery system for cancer treatment. Chem Commun (Camb). 2014; 50(57):7690-3. DOI: 10.1039/c4cc02878c. View

14.

Bialucha C, Collins S, Li X, Saxena P, Zhang X, Durr C . Discovery and Optimization of HKT288, a Cadherin-6-Targeting ADC for the Treatment of Ovarian and Renal Cancers. Cancer Discov. 2017; 7(9):1030-1045. DOI: 10.1158/2159-8290.CD-16-1414. View

15.

Sun H, Zhang Y, Zhong Z . Reduction-sensitive polymeric nanomedicines: An emerging multifunctional platform for targeted cancer therapy. Adv Drug Deliv Rev. 2018; 132:16-32. DOI: 10.1016/j.addr.2018.05.007. View

16.

Naumann R, Coleman R, Burger R, Sausville E, Kutarska E, Ghamande S . PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2013; 31(35):4400-6. DOI: 10.1200/JCO.2013.49.7685. View

17.

Wang S, Huang P, Chen X . Hierarchical Targeting Strategy for Enhanced Tumor Tissue Accumulation/Retention and Cellular Internalization. Adv Mater. 2016; 28(34):7340-64. PMC: 5014563. DOI: 10.1002/adma.201601498. View

18.

Laskar P, Somani S, Campbell S, Mullin M, Keating P, Tate R . Camptothecin-based dendrimersomes for gene delivery and redox-responsive drug delivery to cancer cells. Nanoscale. 2019; 11(42):20058-20071. DOI: 10.1039/c9nr07254c. View

19.

Bargh J, Isidro-Llobet A, Parker J, Spring D . Cleavable linkers in antibody-drug conjugates. Chem Soc Rev. 2019; 48(16):4361-4374. DOI: 10.1039/c8cs00676h. View

20.

Sui B, Cheng C, Wang M, Hopkins E, Xu P . Heterotargeted Nanococktail with Traceless Linkers for Eradicating Cancer. Adv Funct Mater. 2020; 29(50). PMC: 7546548. DOI: 10.1002/adfm.201906433. View